Ganaton (itopride) / Abbott - LARVOL DELTA

One-Pot Biphasic Photocatalytic CO2-to-Carbonylation Cascades. (PubMed, Angew Chem Int Ed Engl) - "This bioinspired compartmentalization enables the photocatalytic reduction of aqueous CO2 by water-soluble catalysts and dyes to produce CO, which then moves into the more buoyant organic layer and is consumed in aminocarbonylation or carbonylative variants of Sonogashira and Suzuki couplings, including the synthesis of the pharmaceutical itopride. The reaction compartmentalization significantly increases the biomimicry of CO2 utilization by enabling the light-driven generation and utilization of CO from CO2 for chemical synthesis in the same pot compared to previous two-pot approaches. The fundamental platform and design criteria described herein can enable future reactions to utilize building blocks as abundant as CO2 to generate complex molecules through bioinspired pathways."

Journal

Effect of Itopride on Semaglutide Gastroparesis (clinicaltrials.gov) - P4 | N=60 | Completed | Sponsor: Ain Shams University | Recruiting ➔ Completed | Trial completion date: Apr 2026 ➔ Jul 2026 | Trial primary completion date: Apr 2026 ➔ Jul 2026

Trial completion • Trial completion date • Trial primary completion date • Anesthesia • Gastrointestinal Disorder

A Quantitative Symptom-Therapy Efficacy Matching Matrix for Precision Treatment Selection in Functional Dyspepsia (ACG 2026) - "Quantitative efficacy data were extracted from five RCTs that report on five different drugs - acotiamide, itopride, buspirone, lansoprazole, and nortriptyline . Matrix-guided therapy selection demonstrated superior match scores across all profiles: pure PDS (itopride 0.317, acotiamide 0.231), pure EPS (itopride 0.307, tricyclic antidepressants 0.218, proton pump inhibitors 0.212), and nausea-dominant (itopride 0.403, tricyclic antidepressants 0.264). K-means clustering confirmed Rome IV subtype separation (k=3, silhouette score 0.771). Monte Carlo validation showed model-guided responder rates exceeded empiric care by 21â28% across profiles, with simulation error < 4% versus published RCT benchmarks."

Clinical • Dyspepsia • Musculoskeletal Pain

Domperidone plus pinaverium bromide and itopride for functional dyspepsia in the elderly: efficacy, symptom improvement, and gastric function panel. (PubMed, Am J Transl Res) - "The triple therapy (DPD+PB+ITP) demonstrates high therapeutic efficacy on elderly FD patients, helps improve symptoms, and actively up-regulates GF panel levels."

Journal • Dyspepsia • GAST

Vonoprazan Alone vs With Itopride for Functional Dyspepsia: The VIVA Trial (clinicaltrials.gov) - P=N/A | N=192 | Recruiting | Sponsor: Asian Institute of Gastroenterology, India

Monotherapy • New trial • Dyspepsia

Pioneering Novel, Green, White, and Blue Fluorescence-Based Platforms for Sustainable and Concurrent Monitoring of Ciprofloxacin With Celecoxib or Itopride in Biological Matrices. (PubMed, Luminescence) - "Moreover, whiteness and blueness evaluations highlighted the favorable integration of analytical efficiency with sustainability principles. The proposed strategies combine rapidity, high sensitivity, and environmental safety, providing reliable alternatives for routine quality control of pharmaceutical formulations and accurate determination of CPN mixtures in biological matrices."

Journal

Alternative Therapeutic Approaches in the Management of Gastroparesis: A Systematic Review. (PubMed, Diseases) - "We found that alternative therapies are effective for the management of gastroparesis. However, the review was limited by heterogeneous study designs, incomplete methodological reporting, and publication bias. Future investigations must focus on long-term randomised control trials encompassing large sample sizes."

Journal • Review • Gastrointestinal Disorder

Itopride as a Potential Drug Against Cancer (Breast and Prostate), by Repurposing Determined Through AI. (PubMed, Arch Pharm (Weinheim)) - "This is justified by the cytotoxic and antiproliferative effects of Itopride observed in vitro cultures. Currently, Itopride is available in several countries and is primarily used as a prokinetic agent and for functional dyspepsia."

Journal • Breast Cancer • Dyspepsia • Genito-urinary Cancer • Infectious Disease • Novel Coronavirus Disease • Oncology • Prostate Cancer • Solid Tumor

Real-world study on efficacy and safety of pancreatin enteric-coated capsules in treatment of postprandial distress syndrome in older patients. (PubMed, Saudi J Gastroenterol) - "PECC monotherapy effectively and safely treats PDS, with efficacy comparable to itopride monotherapy and combination therapy with pancreatin and itopride."

Journal • Real-world evidence • CNS Disorders • Depression • Dyspepsia • General Anxiety Disorder • Mood Disorders • Psychiatry

RETRACTED: Badr et al. Design and Evaluation of S-Protected Thiolated-Based Itopride Hydrochloride Polymeric Nanocrystals for Functional Dyspepsia: QbD-Driven Optimization, In Situ, In Vitro, and In Vivo Investigation. Pharmaceuticals 2023, 16, 925. (PubMed, Pharmaceuticals (Basel)) - "The journal retracts the article cited above, titled "Design and Evaluation of S-Protected Thiolated-Based Itopride Hydrochloride Polymeric Nanocrystals for Functional Dyspepsia: QbD-Driven Optimization, In Situ, In Vitro, and In Vivo Investigation" [...]."

Journal • Preclinical • Dyspepsia

Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia (clinicaltrials.gov) - P3 | N=564 | Completed | Sponsor: Abbott | Active, not recruiting ➔ Completed

Head-to-Head • Trial completion • Dyspepsia • Gastrointestinal Disorder

Optimization and evaluation of gastro-expandable film of Eudragit S100 and ethylcellulose by using the design of experiment. (PubMed, Sci Rep) - No abstract available

Journal

From data mining to experimental validation: ST36 and CV12 as core acupoint combination for acupuncture in functional dyspepsia. (PubMed, Front Med (Lausanne)) - "The rats were randomly assigned to control, model, electroacupuncture, and Itopride groups (n = 6 per group)...This study showed that ST36 and CV12 are the core acupoint combination of acupuncture for FD. Animal experiments further demonstrated that electroacupuncture stimulation of these two acupoints could significantly alleviate the duodenal low-grade inflammation and mucosal barrier damage in FD rats."

Journal • Dyspepsia • Inflammation • CLDN1 • OCLN

Comparing Acotiamide and Itopride for the Management of Indigestion (clinicaltrials.gov) - P4 | N=368 | Not yet recruiting | Sponsor: Aga Khan University

Head-to-Head • New P4 trial • Dyspepsia

Central and Peripheral Neuromodulators in Functional Dyspepsia and Gastroparesis: A Symptom-Based Clinical Review. (PubMed, Neurogastroenterol Motil) - "Neuromodulators provide a rational, mechanism-based treatment option for FD and GP, and a symptom-oriented approach may optimize patient outcomes; although high-quality, subtype-specific trials are needed to strengthen the evidence base."

Journal • Review • Cardiovascular • CNS Disorders • Dyspepsia • Gastrointestinal Disorder • Immunology • Infectious Disease • Musculoskeletal Pain • Pain • Psychiatry

Efficacy and safety of acupuncture for functional dyspepsia: an updated meta-analysis of randomized controlled trials. (PubMed, Front Med (Lausanne)) - "When compared with prokinetics (itopride, mosapride, and domperidone), acupuncture probably improves quality of life (WMD 5.69 points on the 100-point NDLQI, 95% CI 4.36 to 7.02) and may improve FD symptoms (WMD -17.40 points on the 195-point NDSI, 95% CI -29.08 to -5.72). Acupuncture probably improves FD symptoms and quality of life when compared with sham acupuncture, no treatment or usual care, and prokinetics. https://doi.org/10.1002/14651858.CD008487."

Journal • Retrospective data • Review • Dyspepsia

Impact of itopride on functional dyspepsia symptom progression: a multicenter noninterventional postregistration study. (PubMed, Therap Adv Gastroenterol) - "The findings support the use of itopride in clinical settings, providing evidence of its benefit in managing this challenging condition. This study brings additional clinical knowledge from the eastern European population (Czechs) to data published by the ROME IV foundation with various cohorts of patients with FD and its results further demonstrate the long-term benefits and safety profile of itopride with minimal non-AEs."

Clinical • Journal • Dyspepsia • Musculoskeletal Pain • Pain

Effect of Itopride on Semaglutide Gastroparesis (clinicaltrials.gov) - P4 | N=60 | Recruiting | Sponsor: Ain Shams University

New P4 trial • Anesthesia • Gastrointestinal Disorder

Quality by design approach for optimization, in-vitro and in-vivo evaluation of compression-spheronized itopride hydrochloride loaded gastroretentive pellets for the treatment of gastroesophageal reflux disease. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "In vivo gastric residence time was observed to be 6 h, with a bioavailability of 52.87 ± 0.15 µg/mL/h. Based on in vitro and in vivo findings, the developed gastroretentive mucoadhesive pellet formulation presents a promising drug delivery system for the treatment of GERD, potentially enhancing drug efficacy through prolonged gastric retention."

Journal • Preclinical • Gastroenterology • Gastroesophageal Reflux Disease

ITOPRIDE'S ROLE IN FUNCTIONAL DYSPEPSIA: A META-ANALYSIS OF PLACEBO-CONTROLLED AND PROKINETIC-CONTROLLED TRIALS (UEGW 2025) - "Aims & This meta-analysis evaluates the therapeutic efficacy of Itopride compared to placebo and other prokinetic agents in managing FD symptoms.A total of 19 randomized controlled trials were included in the analysis, comprising six placebo-controlled studies (n=1981, 976 on placebo and 1005 on Itopride) and 13 trials comparing Itopride to another prokinetic (n=1077, 515 on Itopride and 562 on control prokinetics including mosapride citrate, levosulpiride, metoclopramide, domperidone, and cisapride). This meta-analysis suggests that Itopride provides significant symptom relief in patients with FD compared to placebo, particularly in overall responder rates. While Itopride's benefits over other prokinetics were modest in general symptom relief, it demonstrated a statistically significant advantage over domperidone for early satiation."

Retrospective data • Dyspepsia • DRD2

Acotiamide vs Itopride in Postprandial Distress Syndrome (clinicaltrials.gov) - P3 | N=152 | Not yet recruiting | Sponsor: Getz Pharma

New P3 trial • Dyspepsia

PASSPORT: Postprandial Distress Itopride Cohort Trial (clinicaltrials.gov) - P=N/A | N=200 | Not yet recruiting | Sponsor: Universitaire Ziekenhuizen KU Leuven

New trial • Dyspepsia • Musculoskeletal Pain • Pain

Therapeutic Efficacy of Flupentixol-Melitracen for Treatment of Aerophagia in Adults: A Single-Center Parallel Randomized Controlled Trial. (PubMed, JGH Open) - P4 | "Groups 1, 2, and 3 were treated with itopride hydrochloride, flupentixol-melitracen, and the combination of two medicines, respectively. The findings suggest that short-term treatment with flupentixol-melitracen, with or without a prokinetic benzamide derivative, is likely to improve symptoms of aerophagia in adults without significant adverse effects. Trial Registration: ClinicalTrials.gov identifier: ChiCTR-IPR-15006869."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Proposed Algorithm for the Diagnosis and Management of Diabetic Gastroparesis in the Indian Clinical Setting. (PubMed, Indian J Endocrinol Metab) - "Additionally, the algorithm underscores the significance of endoscopic evaluation and gastric emptying studies in DGP diagnosis, as well as the use of prokinetics, antiemetics, and neuromodulators in treatment. Notably, the experts favoured itopride as the preferred and relatively safer prokinetic for treating DGP and its varied clinical presentations."

Journal • Review • Anorexia • Diabetes • Gastrointestinal Disorder • Metabolic Disorders

Functional disorders of the upper digestive tract: epidemiological, clinical and therapeutic aspects. (PubMed, Recenti Prog Med) - "First-line drugs for the management of functional dyspepsia include prokinetics, such as domperidone and itopride, and proton pump inhibitors, the latter being indicated mainly in patients with symptoms associated with hyperacidity. However, current guidelines emphasize the need for further clinical evidence to consider such approaches as standard of care. In conclusion, although significant progress has been made in the understanding and treatment of these disorders, there remains much room for development with regard to targeted and personalized therapeutic strategies."

Journal • Review • Dyspepsia • Gastrointestinal Disorder • Immunology • Musculoskeletal Pain • Pain